117 related articles for article (PubMed ID: 9774962)
21. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
Bow EJ; Sutherland JA; Kilpatrick MG; Williams GJ; Clinch JJ; Shore TB; Rubinger M; Schacter BA
J Clin Oncol; 1996 Apr; 14(4):1345-52. PubMed ID: 8648393
[TBL] [Abstract][Full Text] [Related]
22. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
23. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.
Matthews JP; Bishop JF; Young GA; Juneja SK; Lowenthal RM; Garson OM; Cobcroft RG; Dodds AJ; Enno A; Gillett EA; Hermann RP; Joshua DE; Ma DD; Szer J; Taylor KM; Wolf M; Bradstock KF;
Br J Haematol; 2001 Jun; 113(3):727-36. PubMed ID: 11380464
[TBL] [Abstract][Full Text] [Related]
24. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
25. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Zittoun R; Liso V; Mandelli F; Rotoli B; de Witte T; Gattringer C; Resegotti L; Caronia F; Leoni P; Petti MC
Leukemia; 1992; 6 Suppl 2():76-7. PubMed ID: 1578949
[No Abstract] [Full Text] [Related]
26. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
27. DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia.
Hwang WL; Young JH; Gau JP; Hu HT; Tsai YT
Am J Clin Oncol; 1992 Dec; 15(6):531-4. PubMed ID: 1449119
[TBL] [Abstract][Full Text] [Related]
28. Is allogeneic bone marrow transplantation the best treatment for young adult patients with acute myeloid leukemia in first complete remission. The BGMT Group.
Reiffers J; Stoppa AM; Rigal-Huguet F; Michallet M; Marit G; Blaise D; Attal M; Corront B; Cony-Makhoul P; Gastaut JA
Leukemia; 1992; 6 Suppl 2():124-6. PubMed ID: 1578913
[No Abstract] [Full Text] [Related]
29. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Jehn U; Suciu S; Thomas X; Lefrère F; Muus P; Berneman Z; Marie JP; Adamo F; Fillet G; Nobile F; Ricciuti F; Leone G; Rizzoli V; Montanaro M; Beeldens F; Fazi P; Mandelli F; Willemze R; de Witte T; Amadori S
Leukemia; 2006 Oct; 20(10):1723-30. PubMed ID: 16932345
[TBL] [Abstract][Full Text] [Related]
30. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
31. Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Harousseau JL; Milpied N; Briere J; Desablens B; Leprise PY; Ifrah N; Gandhour B; Casassus P
Semin Hematol; 1991 Jul; 28(3 Suppl 4):80-3. PubMed ID: 1780758
[No Abstract] [Full Text] [Related]
32. SAB--a promising new treatment to improve remission rates in AML in the elderly?
Wheatley K
Br J Haematol; 2002 Aug; 118(2):432-3. PubMed ID: 12139727
[TBL] [Abstract][Full Text] [Related]
33. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
[TBL] [Abstract][Full Text] [Related]
34. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.
Büchner T; Hiddemann W; Löffler G; Gassmann W; Maschmeyer G; Heit W; Hossfeld D; Weh H; Ludwig WD; Thiel E
Semin Hematol; 1991 Jul; 28(3 Suppl 4):76-9. PubMed ID: 1780757
[No Abstract] [Full Text] [Related]
35. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Gruber A; Björkholm M; Brinch L; Evensen S; Gustavsson B; Hedenus M; Juliusson G; Löfvenberg E; Nesthus I; Simonsson B; Sjo M; Stenke L; Tangen JM; Tidefelt U; Udén AM; Paul C; Liliemark J
Leuk Res; 2003 Apr; 27(4):323-8. PubMed ID: 12531223
[TBL] [Abstract][Full Text] [Related]
36. High-dose cytarabine induction for acute myeloid leukemia.
Shepherd JD; Barnett MJ; Philips GL
Blood; 1996 Jul; 88(2):754-5. PubMed ID: 8695826
[No Abstract] [Full Text] [Related]
37. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
38. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults.
Ohno R; Yokomaku S; Okumura M; Nagai T; Kitaori K; Ito T; Takeo T; Sugiura I; Yano K; Ito Y
Int J Hematol; 1991 Dec; 54(6):487-93. PubMed ID: 1793832
[TBL] [Abstract][Full Text] [Related]
39. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
40. [The therapeutic results in acute myeloid leukemias in elderly patients].
Parovichnikova EN; Savchenko VG; Isaev VG; Tikhonova LIu; Sarycheva TG; Kulikov SM
Ter Arkh; 1992; 64(8):87-9. PubMed ID: 1440406
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
